Tenaya Therapeutics remains pre-revenues, and it’s a thinly traded microcap. Its tight cash runway is also a concern. Read ...

Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

Final 5-year data from the phase 2 2102-HEM-101 trial (NCT02719574) show that olutasidenib (Rezlidhia; Rigel Pharmaceuticals, ...

New approaches hurdle biological barriers to attack recalcitrant targets to tackle difficult-to-treat and recurrent cancers.

Owkin shares promising validation results for BRCAura RUO, a clinical-grade research-use-only AI product designed to screen for germline BRCA1/2 mutations (gBRCAm) directly from digitized breast ...

MS. COOPER: Good morning, and welcome to The Washington Post. I’m Gina Cooper, managing director of Washington Post Live. Thank you so much to everyone who’s here in the room joining us this morning ...

Citi Annual Global Healthcare Conference 2025 December 4, 2025 10:30 AM ESTCompany ParticipantsMatthew Klein - CEO ...

Researchers at Helmholtz Munich, the Technical University of Munich and the LMU University Hospital Munich uncovered a ...

DS-1594b showed on-target biological activity but failed to achieve protocol-defined responses, leading to early trial termination. Differentiation syndrome occurred in 29.4% of patients, prompting ...

Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses([1]) , while ...

This satellite symposium at the European Society for Medical Oncology (ESMO) Congress 2025, chaired by Rana McKay, Professor ...